Medication info
Fios Tablets (Pioglitazone Hydrochloride)

Fios Tablets (Pioglitazone Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Pioglitazone Hydrochloride›16.53mg / 1 tablet
Manufacturer / importer
Kips Biopharma Co., Ltd.
Appearance
White round tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 200703460 · Notified 2007.03.27 · Insurance code 693200550

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
Administer orally once daily, regardless of meals. If glycemic control does not worsen in patients with diabetes, treatment should be continued for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. Monotherapy: In patients whose blood glucose is not adequately controlled by diet and exercise, treatment may be initiated with pioglitazone 15 mg once daily. If the initial dose does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. Combination therapy with a sulfonylurea: The initial dose is 15 mg once daily. The current sulfonylurea may be continued at the same dose and schedule. If the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. Combination therapy with metformin: The initial dose is 15 mg once daily. The current metformin may be continued at the same dose and schedule. Combination therapy with insulin: Administer 15 mg once daily. The current insulin dose may be maintained when combination therapy is initiated. If the patient develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose: For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment. Do not initiate treatment with this drug if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal).
Child dose
Under 18 years of age: Use is not recommended because there is no experience with use in this age group.

Ingredients

Manufacturer
Kips Biopharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control disorders in patients with Type 2 diabetes
View approved original text

This medication is used to help control blood sugar levels in patients with Type 2 diabetes. It can be administered alone and may also be used in combination with sulfonylureas, metformin, or insulin if there is no improvement in blood sugar when using other oral hypoglycemic agents. Along with drug therapy, dietary therapy, exercise therapy, and, if necessary, weight loss and nutritional counseling are important. Especially, these lifestyle improvement efforts are necessary not only for initial treatment but also to maintain the effectiveness of long-term drug therapy. This medication helps to effectively improve your blood sugar levels.

How to take

Adult dose

Administer orally once daily, regardless of meals. If glycemic control does not worsen in patients with diabetes, treatment should be continued for an appropriate period (at least 3 months) to assess changes in glycated hemoglobin. Monotherapy: In patients whose blood glucose is not adequately controlled by diet and exercise, treatment may be initiated with pioglitazone 15 mg once daily. If the initial dose does not provide sufficient efficacy, the dose may be increased to 30 mg once daily. Combination therapy with a sulfonylurea: The initial dose is 15 mg once daily. The current sulfonylurea may be continued at the same dose and schedule. If the patient develops symptoms of hypoglycemia, the sulfonylurea dose should be reduced. Combination therapy with metformin: The initial dose is 15 mg once daily. The current metformin may be continued at the same dose and schedule. Combination therapy with insulin: Administer 15 mg once daily. The current insulin dose may be maintained when combination therapy is initiated. If the patient develops symptoms of hypoglycemia or the plasma glucose concentration decreases to 100 mg/dL or below, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose: For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment. Do not initiate treatment with this drug if, at the start of therapy, the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal).

Child dose

Under 18 years of age: Use is not recommended because there is no experience with use in this age group.

Precautions

This medication may cause or worsen heart failure in some patients, so changes in weight, breathing difficulties, edema, and other symptoms should be carefully monitored after administration. It should not be used in patients with heart failure or a history of heart failure. This medication may cause fluid retention when used with insulin; therefore, it should be used cautiously in patients at risk of heart failure. If blood in urine or urination disorders occur during treatment, there may be a possibility of bladder cancer, and you must notify your doctor immediately. It should not be administered to those with hypersensitivity to this medication or in patients with liver impairment, severe renal impairment, diabetic ketoacidosis, or Type 1 diabetes. Patients taking other oral hypoglycemic agents or those with edema, myocardial infarction, hypertensive heart diseases, or any heart conditions should use it with caution. Side effects may occur, including upper respiratory infections, headaches, edema, weight gain, and hypoglycemia, and particular attention should be paid to the potential occurrence of hypoglycemia and edema. If symptoms of abnormal liver function appear, immediate medical attention and necessary tests must be performed, and if liver enzyme levels significantly increase, administration should be discontinued. Pregnant women or those who may become pregnant should avoid using this medication, and premenopausal women should take adequate contraceptive measures to account for the increased risk of pregnancy. The safety and efficacy of this medication have not been established in children under 18 years of age, and caution should be exercised in elderly patients over 75 years of age. In cases of overdose, appropriate treatment should be administered based on symptoms, and it should be kept out of reach of children. This medication may interact with other drugs, so inform your doctor or pharmacist if you are taking any other medications. Regular monitoring of blood sugar and liver function tests is important throughout the treatment to check for abnormalities.

Side effects

Congestive heart failure, excessive and rapid weight change, dyspnea, edema, fluid retention, inadequate blood sugar control, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal bloating, weight gain, hypoglycemia, urinary tract infection, lumbago, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, worsening of congestive heart failure, emergency room visits due to congestive heart failure, edema-related adverse reactions, increased serum ALT levels, liver failure, vision reduction, diabetic macular edema, increased blood sugar, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, dyspnea, itching, discomfort in the chest, tremors, chills, gastrointestinal diseases, abdominal pain, epigastric discomfort, numbness, muscle rigidity, discomfort in the head, increased liver enzymes, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased serum creatinine, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, cardiac dysfunction, fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or humidity; therefore, it should be stored in a sealed container. It is best to maintain an ambient temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.